The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy.

Badaoui, Sarah; Shahnam, Adel; McKinnon, Ross A; Abuhelwa, Ahmad Y; Sorich, Michael J; Hopkins, Ashley M

Badaoui, Sarah; Shahnam, Adel; McKinnon, Ross A; Abuhelwa, Ahmad Y; Sorich, Michael J; Hopkins, Ashley M.

Afiliação

Badaoui S; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Shahnam A; Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, New South Wales, Australia.
McKinnon RA; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Abuhelwa AY; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Sorich MJ; College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Hopkins AM; College of Medicine and Public Health, Flinders University, Adelaide, Australia.

Transl Lung Cancer Res ; 11(3): 432-439, 2022 Mar.

Article em En | MEDLINE | ID: mdl-35399575

Palavras-chave

Patient-reported outcomes; immunotherapy; non-small cell lung cancer (NSCLC); prognosis; survival

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google